Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023-2032

Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023-2032

Global Lung Cancer Treatment Market size will grow substantially during 2023-2032. Rising air pollution levels due to accelerating urbanization and industrial growth worldwide have resulted in increased incidences of lung cancer, bolstering the need for its treatment. As per the WHO, ambient air pollution is projected to lead to 16% of lung cancer deaths, while air pollution may be responsible for around 29% of the deaths caused by lung cancer globally. The increasing disease burden has bolstered awareness about its early diagnosis and treatment to prevent further complications, contributing to market growth.

The overall lung cancer treatment market is segmented based on type, therapy, end-user, and region.

Based on type, the market share from the carcinoid segment will depict significant growth through 2032. Growing prevalence of lung cancer and high mortality rate associated with it has increased the need for its treatment. According to the American Cancer Society, the U.S. reports around 2,000 to 4,500 lung carcinoid tumors every year. Moreover, improved diagnostic techniques and the rising awareness of carcinoid tumors have propelled the number of patients undergoing treatment of this condition, thus, adding to market revenue.

In terms of therapy, the lung cancer treatment market value from the chemotherapy segment will accrue significant gains through 2032. Advances in genomics and molecular profiling have enabled personalized medicine in chemotherapy. By analyzing a patient's tumor at a molecular level, doctors can identify specific genetic mutations or biomarkers that drive the cancer's growth. This information helps tailor the chemotherapy regimen to target those specific abnormalities, increasing treatment effectiveness.

Based on end-user, the lung cancer treatment market from the specialty clinics segment will observe appreciable growth over 2023-2032. High availability of cutting-edge diagnostic equipment has made specialty clinics a preferred healthcare provider. Additionally, these facilities are well-positioned to provide personalized care tailored to specific patient needs. They offer comprehensive evaluations, molecular profiling, and access to clinical trials, ensuring that patients receive the most appropriate and effective treatment options.

Regionally, Europe lung cancer treatment industry will grow at a decent CAGR from 2023 to 2032. High incidence rate of lung cancer has increased the need for its treatment in the region. Moreover, a strong presence of industry contenders such as Boehringer Ingelheim International GmbH, Merck KGaA, and others constantly focusing on developing advanced treatment options for lung cancer is positively impacting the regional market growth. Additionally, the rapid expansion of the existing healthcare infrastructure in the region will stimulate industry revenue streams through 2032.